Next Article in Journal
Deregulation of Negative Controls on TGF-β1 Signaling in Tumor Progression
Next Article in Special Issue
Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia
Previous Article in Journal
Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor)
Review

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML

1
Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany
2
National Center for Tumor Diseases (NCT), University Hospital Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany
3
German Cancer Consortium (DKTK), 01307 Dresden, Germany
4
German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Received: 24 April 2018 / Revised: 19 May 2018 / Accepted: 21 May 2018 / Published: 24 May 2018
(This article belongs to the Special Issue Treatment of Older Adults with Acute Myeloid Leukemia)
Higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) of the elderly exhibit several commonalities, including first line treatment with hypomethylating agents (HMA) like azacitidine (AZA) or decitabine (DAC). Until today, response to treatment occurs in less than 50 percent of patients, and is often short-lived. Moreover, patients failing HMA have a dismal prognosis. Current developments include combinations of HMA with novel drugs targeting epigenetic or immunomodulatory pathways. Other efforts focus on the prevention of resistance to HMA using checkpoint inhibitors to enhance immune attack. This review focuses on recent advances in the field of HMA-based front-line therapies in elderly patients with myeloid diseases. View Full-Text
Keywords: HMA; elderly AML; combination strategies; checkpoint inhibition HMA; elderly AML; combination strategies; checkpoint inhibition
MDPI and ACS Style

Kubasch, A.S.; Platzbecker, U. Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML. Cancers 2018, 10, 158. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10060158

AMA Style

Kubasch AS, Platzbecker U. Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML. Cancers. 2018; 10(6):158. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10060158

Chicago/Turabian Style

Kubasch, Anne S., and Uwe Platzbecker. 2018. "Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML" Cancers 10, no. 6: 158. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10060158

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop